Cariprazine

Vraylar, Reagila (cariprazine) is a small molecule pharmaceutical. Cariprazine was first approved as Vraylar on 2015-09-17. It is used to treat bipolar disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor and D(3) dopamine receptor. Vraylar's patents are valid until 2029-09-17 (FDA).